Malignant Hyperthermia

Kay 1 Amy Kay Professor Robinson Medical Terminology October 12, 2005 malignant hyperthermy Malignant Hyperthermia (MH) is a pharmacogenetic disease of skeletal vigor. Characteristically patients with this disease harbour no signs or symptoms except during an anesthetic. When exposed to inhalational anesthetics (those which are gases), muscle metabolism summations, and a series of signs and symptoms appear, which if left untreated shadower depart to death. The earliest findings are an increased production of ampere-second paper dioxide and signs of increases sympathetic nervous musical arrangement activity. Malignant Hyperthermia is typically a life threatening disease, also referred to as a syndrome, which occurs when a person with Malignant Hyperthermia susceptibility indication is exposed to triggering factors, which include most inhalational anesthetics (though not Nitrous Oxide), succinylcholine ( a muscle relaxant used during surgery) and rarely stress. Classic Malignant Hyperthermia is characterized by hypermetabolism, (increased oxygen consumption and increased carbon dioxide production) muscle rigidity, muscle injury, and increased sympathetic nervous system activity.

Hypermetabolism reflected by elevated carbon dioxide Kay 2 production precedes the increase in body temperature. (http://www.mhaus.org) In muscle contraction atomic number 20 is released into the cell as a key component in muscle contraction. In MH there is a problem with calcium reuptake. Intracellular calcium increases up 500 fold take to substained muscle contraction. The cell incurs a severe oxygen debt, the unvaried demand for ATP leads to glycolysis and subsequent to lactic acidosis. Eventually this lead to membrane instability, cell rupture and rhabdomyolysis. (http://www.mhaus.org) MH is important because it is a potentially fatal disorder. In April 2005... If you want to get a fully essay, order it on our website: Orderessay

If you want to get a full essay, wisit our page: write my essay .